ACCESS Newswire

Northway Biotech

24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release

Share
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts

WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts

This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.

Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."

To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.

About Northway Biotech - https://www.northwaybiotech.com

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.

For Further Information, Contact:

Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

SOURCE: Northway Biotech

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Transoft Solutions Launches InSTRATO1.10.2026 20:30:00 CEST | Press release

VANCOUVER, BC / ACCESS Newswire / October 1, 2026 / Transoft Solutions, a global leader in transportation engineering software and road safety solutions, has launched InSTRATO, a new web-based platform for transportation engineers, planners, and designers. This platform brings specialized transportation design tools together with new ways for professionals to share work, gather feedback, and collaborate throughout the project process. The launch marks the next chapter for AutoTURN Online, Transoft's web-based swept path analysis solution. AutoTURN Online will now be available within InSTRATO, continuing to provide the same trusted simulation technology and vehicle libraries users rely on today while opening the door to a broader set of transportation design and collaboration capabilities. "Since 2018, AutoTURN Online has helped more than 110,000 practitioners perform swept path analysis on the web, supporting design decisions that affect how people and vehicles move through the world.

ID TECH and SFEY Partner to Deliver Comprehensive Payment Solutions for Europe's Self-Service and Unattended Markets1.10.2026 19:00:00 CEST | Press release

CYPRESS, CA / ACCESS Newswire / October 1, 2026 / ID TECH, a global provider of secure payment solutions, today announced a strategic partnership with SFEY to deliver a comprehensive payment offering for the European self-service, unattended and transit market. The collaboration brings together ID TECH's industry-leading unattended payment hardware portfolio with SFEY's dynamic payment gateway and platform capabilities, creating an integrated solution designed to simplify deployment and accelerate time to market for system integrators across Europe. Together, the companies will support a broad range of unattended applications including self-service, kiosk, and transportation environments, with a scalable payment ecosystem built to meet evolving market requirements. A key area of focus within the partnership is support for mass transit and open-loop transit payment programs, leveraging SFEY's payment platform capabilities and certification expertise alongside ID TECH's transit-ready pay

Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release

ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the

Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release

HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy

Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye